SHENZHEN, China, Dec. 16, 2024 — Fangzhou Inc. (“Fangzhou” or the “Company”) (06086.HK), a leading provider of online healthcare solutions, received the “Most Valued Pharmaceutical & Healthcare Enterprise” award at the ninth annual Zhitong Finance Capital Market Summit and Listed Company Gala in Shenzhen, China.
Fangzhou’s Chairman and CEO, Mr. Xie Fangmin, commented on the award, stating, “This recognition affirms our commitment to technological innovation and the growth of the internet healthcare sector.”
The “Most Valued Pharmaceutical & Healthcare Enterprise” award is given to outstanding pharmaceutical and healthcare companies listed in Hong Kong and the United States, based on their strong corporate governance, market leadership, and financial performance.
Fangzhou, a pioneer in online healthcare, has been listed on the Hong Kong Stock Exchange’s main board since July 2024 and was added to the Hang Seng Hong Kong-Listed Biotech Index (“HSHKBIO”) on December 9, 2024.
Fangzhou has utilized advanced technologies, such as AI and big data, to improve its chronic disease management platform and enhance the experience for both patients and doctors. This award underscores the company’s significant industry standing and ongoing dedication to online healthcare innovation.
About Fangzhou Inc.
Fangzhou Inc. (06086.HK) is China’s leading online platform for managing chronic diseases. With 45.6 million registered users and 217,000 registered doctors (as of June 30, 2024), the Company offers personalized medical care and precision medicine to a growing number of patients with chronic illnesses. For more details, visit .
About the Zhitong Finance Capital Market Summit and Listed Company Gala
The “9th Zhitong Finance Capital Market Summit and Listed Company Gala ” was a joint venture between Zhitong Finance, a prominent Hong Kong and U.S. stock information platform, and New Wisdom Fund Network, a comprehensive service platform for Chinese overseas private equity funds. The event brought together key figures from leading international and domestic financial institutions and chief economists, alongside over 300 senior executives from Hong Kong and U.S. listed companies, 100+ U.S. equity funds and more than 1,000 professional investors, to discuss investment prospects in Chinese assets for 2025. Over nine years, this summit has established a strong reputation and influence within the nation’s capital markets.
Media Contact
For further inquiries or interviews, please reach out to:
Xingwei Zhao Associate Director of Public Relations Email:
Disclaimer: This press release includes forward-looking statements. Actual results may vary significantly due to several factors. Readers should avoid undue reliance on these statements
SOURCE Fangzhou Inc.